RT Journal Article
SR Electronic
T1 Effects of temperature on COVID-19 transmission
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.29.20044461
DO 10.1101/2020.03.29.20044461
A1 Pawar, Shrikant
A1 Stanam, Aditya
A1 Chaudhari, Mamata
A1 Rayudu, Durga
YR 2020
UL http://medrxiv.org/content/early/2020/03/30/2020.03.29.20044461.abstract
AB Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it was first identified in 2019 in Wuhan, China and has resulted in the 2019–20 coronavirus pandemic. As of March 1, 2020, 79,968 patients in China and 7169 outside of China had tested positive for COVID-19 and a mortality rate of 3.6% has been observed amongst Chinese patients. Its primary mode of transmission is via respiratory droplets from coughs and sneezes. The virus can remain viable for up to three days on plastic and stainless steel or in aerosols for upto 3 hours and is relatively more stable than the known human coronaviruses. It is stable in faeces at room temperature for at least 1-2 days and can be stable in infected patients for up to 4 days. Heat at 56°C kills the SARS coronavirus at around 10000 units per 15 minutes. Thus, temperature is an important factor in survival of COVID-19 virus and this article focuses on understanding the relationship between temperature and COVID-19 transmission from the data available between January-March 2020.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding has been utilized.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this study is not publicly available, but can be obtained by emailing the corresponding author.